Browse by author
Lookup NU author(s): Dr Simon Bridge, Dr David Sheridan, Dr R Neely, Emeritus Professor Margaret Bassendine
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Copyright © 2025 Bridge, Pagano, Lodge, Shawa, Marin-Crespo, Cramp, Sheridan, Taylor-Robinson, Vuilleumier, Neely and Bassendine. Background: Chronic HCV (CHC) infection is associated with autoimmunity. IgG autoantibodies to apolipoprotein A-I (AAA-I) predict all-cause mortality. We evaluated AAA-I in CHC patients and in those who were not viraemic, either because of spontaneous resolution (SR) of infection or HCV clearance following sustained virological response (SVR) after interferon therapy. We limited the study to HCV genotypes 1 and 3, the dominant HCV genotypes circulating in the UK. Methods: Serum samples from 126 CHC patients and 114 nonviraemic individuals (25 SR and 89 SVR) were assayed for AAA-I and lipoproteins. AUC was calculated for AAA-I and HDL-related parameters and used to predict cirrhosis. Fibronectin (FN) and FN-mRNA were measured in human hepatic stellate cells (LX-2) in the presence or absence of AAA-I. Results: AAA-I was found in 47% of patients with CHC, 37% of SVR patients, and 16% of SR individuals (CHC vs. SR, p = 0.004). AAA-I levels in CHC patients were higher in those with cirrhosis (p = 0.0003). The AUC for AAA-I, apoA-I, and HDL-C in predicting cirrhosis was 0.72 (p < 0.001), 0.65 (p = 0.01), and 0.64 (p = 0.02). After 48 h in the presence of AAA-I, LX-2 cells showed an 80% increase in FN-mRNA compared to the LX-2/IgG control (p = 0.028) and higher levels of FN (p = 0.0016). Conclusions: CHC is often associated with AAA-I, and these can persist after SVR. AAA-I is a robust predictor of cirrhosis in CHC infection. LX-2 cells exposed to AAA-I showed increased FN. Further studies are warranted to define the role of AAA-I in promoting not only viral persistence but also fibrosis.
Author(s): Bridge SH, Pagano S, Lodge JK, Shawa IT, Marin-Crespo P, Cramp ME, Sheridan DA, Taylor-Robinson SD, Vuilleumier N, Neely RDG, Bassendine MF
Publication type: Article
Publication status: Published
Journal: Frontiers in Immunology
Year: 2025
Volume: 16
Online publication date: 20/03/2025
Acceptance date: 05/02/2025
Date deposited: 14/04/2025
ISSN (electronic): 1664-3224
Publisher: Frontiers Media SA
URL: https://doi.org/10.3389/fimmu.2025.1461041
DOI: 10.3389/fimmu.2025.1461041
Data Access Statement: The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Altmetrics provided by Altmetric
